Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial

BMJ Open (Jun 2022)

Affiliations

Ling Wang: Department of Medicine, Michigan State University, East Lansing, Michigan, USA
Xia Chen: 1 Department of Anaesthesiology, Shanghai Jiaotong University First People’s Hospital, Shanghai, China
Juan Zhao: Department of Social Medicine,School of Health Management, Harbin Medical University, Harbin, Heilongjiang, China
Jiaxi Tang: Department of Anesthesiology, Chongqing University Cancer Hospital, Chongqing, China
Wanyan Tang: Department of Phase I Clinical Trial Ward, Chongqing University Cancer Hospital, Chongqing, China
Bin Liao: Department of Phase I Clinical Trial Ward, Chongqing University Cancer Hospital, Chongqing, China
Weiqi Nian: Department of Phase I Clinical Trial Ward, Chongqing University Cancer Hospital, Chongqing, China

Abstract

No abstracts available.